Evidence map›Paper›PMID 39656879›Full record

ArticleCerebral cortex (New York, N.Y. : 1991)2024

Identification and characterization of human KALRN mRNA and Kalirin protein isoforms.

Arne W Mould, David J Wright, Klaus D Bornemann, Bastian Hengerer, Rob Pinnock, Edward Drydale, James Bancroft, Nicola A L Hall, Annette von Delft, Paul E Brennan and 3 more

Abstract read
In one paragraph

Article in Cerebral cortex (New York, N.Y. : 1991), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arne W MouldDepartment of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom.ORCID 0000-0002-2004-4348
David J WrightEarlham Institute, Norwich Research Park, Norwich NR4 7UZ, United Kingdom.
Klaus D BornemannBoehringer Ingelheim Pharma GmbH & Co. KG, 65 Birkendorfer Straße, 88397, Biberach an der Riß, Germany.
Bastian HengererBoehringer Ingelheim Pharma GmbH & Co. KG, 65 Birkendorfer Straße, 88397, Biberach an der Riß, Germany.
Rob PinnockBiogen Idec Ltd, 5 Roxborough Way, Maidenhead SL6 3UD, United Kingdom.
Edward DrydaleCentre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom.
James BancroftCentre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom.
Nicola A L HallDepartment of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom.
Annette von DelftCentre for Medicines Discovery, NDM Research Building, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, United Kingdom.
Paul E BrennanAlzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, NDM Research Building, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, United Kingdom.
Paul J HarrisonDepartment of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom.
Wilfried HaertyEarlham Institute, Norwich Research Park, Norwich NR4 7UZ, United Kingdom.
Elizabeth M TunbridgeDepartment of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom.

Funding

Alzheimer's Research UKBiogen and Boehringer Ingelheim via the Psychiatry Consortium of the Medicines Discovery CatapultBiotechnology and Biological Sciences Research Council BB/CCG1720/1Biotechnology and Biological Sciences Research Council BBS/E/ER/230001ABiotechnology and Biological Sciences Research Council BBS/E/ER/230001CBiotechnology and Biological Sciences Research Council BS/E/T/000PR981National Institute for Health and Care ResearchNIHR Oxford Health Biomedical Research Centre NIHR203316Oxford Health Biomedical Research CentreUKRI BBSRC BB/CCG1720/1
6 · The paper itself

Abstract

Kalirin is a multidomain protein with important roles in neurite outgrowth, and synaptic spine formation and remodeling. Genetic and pathophysiological links with various neuropsychiatric disorders associated with synaptic dysfunction and cognitive impairment have sparked interest in its potential as a pharmacological target. Multiple Kalirin proteoforms are detected in the adult human brain, yet we know little about the diversity of the transcripts that encode them or their tissue profiles. Here, we characterized full-length KALRN transcripts expressed in the adult human frontal lobe and hippocampus using rapid amplification of complementary DNA (cDNA) ends and nanopore long-read sequencing. For comparison with non-neural tissue, we also analyzed KALRN transcripts in the aorta. Multiple novel isoforms were identified and were largely similar between the two brain regions analyzed. Alternative splicing in the brain results in preferential inclusion of exon 37, which encodes 32 amino acids upstream of the second guanine nucleotide exchange factor (GEF) domain. Structural modeling predicts that a subset of these amino acids forms a conserved alpha helix. Although deletion of these amino acids had little effect on GEF activity, it did alter Kalirin-induced neurite outgrowth suggesting that this brain-enriched splicing event may be important for neural function. These data indicate that alternative splicing is potentially important for regulating Kalirin actions in the human brain.

Indexed as

Alternative SplicingGuanine Nucleotide Exchange FactorsHippocampusProtein IsoformsRNA, MessengerAnimalsFrontal LobeHEK293 CellsHumansProtein Serine-Threonine KinasesGuanine Nucleotide Exchange FactorsKALRN protein, humanProtein IsoformsProtein Serine-Threonine KinasesRNA, Messengeralternative splicingGEFRhoGTPasesynaptic plasticity

Identifiers

PMID39656879
PMCPMC11630257

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.